{"success":true,"data":{"pressRelease":{"id":"159684","rtpr_id":"nGNX9l9QT0-20261002","ticker":"SNDX","exchange":"NASDAQ","all_tickers":["SNDX"],"title":"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","author":"Globe Newswire","published_at":"2026-10-02T20:01:00.209Z","article_body":"NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq:\nSNDX), a commercial-stage biopharmaceutical company advancing innovative\ncancer therapies, today announced that on October 1, 2026, the Company granted\ninducement awards to purchase up to 213,300 shares of common stock to nine new\nemployees under the Company's 2023 Inducement Plan. The stock options will\nvest over four years, with 25% of the underlying shares vesting on the\none-year anniversary of the vesting commencement date and 1/48th of the\nunderlying shares vesting monthly thereafter over 36 months, subject to the\nemployee's continued service relationship with Syndax through the applicable\nvesting dates.\n\nAbout Syndax\nSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company\nadvancing innovative cancer therapies. Highlights of the Company's pipeline\ninclude Revuforj(®) (revumenib), an FDA-approved menin inhibitor,\nand Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that\nblocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our\ncommitment to reimagining cancer care, Syndax is working to unlock the full\npotential of its pipeline and is conducting several clinical trials across the\ncontinuum of treatment. For more information, please\nvisit www.syndax.com or follow the Company on X \n(https://www.globenewswire.com/Tracker?data=OB42PPr6bdUdDUZHgJbcek8s9taqOhV4R-L0M4nP51Sn6H7TG2g6zJ8a12RaJ3m49rv24VmI9UJmI1CaK7UwfQ==)and LinkedIn\n(https://www.globenewswire.com/Tracker?data=P1yhCa_b_Bsu4Y93yTHhQdY8PYPlzOIsHzGvmR7b5DW7BXePPCnjOvm6TdkKD6PTW12PdSA45WYb5H9ayHA21p37cV07q9PfmcjVNhyTrF20_1d2VNwR6aNdjKG009Qh).\n\nSyndax Contact\n\nSharon Klahre \nSyndax Pharmaceuticals, Inc. \nsklahre@syndax.com\nTel 781.684.9827\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/399a65b5-bd4f-4ba5-980b-f4d0af9ae6a0)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX9l9QT0-20261002","title":"Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)","author":"Globe Newswire","ticker":"SNDX","created":"2026-10-02T20:01:00.209Z","tickers":["SNDX"],"exchange":"NASDAQ","article_body":"NEW YORK, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq:\nSNDX), a commercial-stage biopharmaceutical company advancing innovative\ncancer therapies, today announced that on October 1, 2026, the Company granted\ninducement awards to purchase up to 213,300 shares of common stock to nine new\nemployees under the Company's 2023 Inducement Plan. The stock options will\nvest over four years, with 25% of the underlying shares vesting on the\none-year anniversary of the vesting commencement date and 1/48th of the\nunderlying shares vesting monthly thereafter over 36 months, subject to the\nemployee's continued service relationship with Syndax through the applicable\nvesting dates.\n\nAbout Syndax\nSyndax Pharmaceuticals is a commercial-stage biopharmaceutical company\nadvancing innovative cancer therapies. Highlights of the Company's pipeline\ninclude Revuforj(®) (revumenib), an FDA-approved menin inhibitor,\nand Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that\nblocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our\ncommitment to reimagining cancer care, Syndax is working to unlock the full\npotential of its pipeline and is conducting several clinical trials across the\ncontinuum of treatment. For more information, please\nvisit www.syndax.com or follow the Company on X \n(https://www.globenewswire.com/Tracker?data=OB42PPr6bdUdDUZHgJbcek8s9taqOhV4R-L0M4nP51Sn6H7TG2g6zJ8a12RaJ3m49rv24VmI9UJmI1CaK7UwfQ==)and LinkedIn\n(https://www.globenewswire.com/Tracker?data=P1yhCa_b_Bsu4Y93yTHhQdY8PYPlzOIsHzGvmR7b5DW7BXePPCnjOvm6TdkKD6PTW12PdSA45WYb5H9ayHA21p37cV07q9PfmcjVNhyTrF20_1d2VNwR6aNdjKG009Qh).\n\nSyndax Contact\n\nSharon Klahre \nSyndax Pharmaceuticals, Inc. \nsklahre@syndax.com\nTel 781.684.9827\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/399a65b5-bd4f-4ba5-980b-f4d0af9ae6a0)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-02T20:01:00.385986103Z","server_sent_at_ms":1790971260385},"received_at":"2026-10-02T20:01:00.435Z","source_url":null},"analysis":{"id":"148276","press_release_id":"159684","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Syndax Pharmaceuticals granted inducement stock options to purchase up to 213,300 shares to nine new employees on October 1, 2026, under its 2023 Inducement Plan.\n\nThe awards vest over four years with a standard one-year cliff at 25%, followed by monthly vesting over 36 months, subject to continued employment.\n\nThis is routine hiring-related equity disclosure under NASDAQ Listing Rule 5635(c)(4) with no bearing on strategy or financials.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine inducement grant disclosure -- suppress."},"keyFigures":{"customDimensions":{"vesting":"4 years; 25% at one-year anniversary, then 1/48th monthly over 36 months","new_employees":9,"inducement_shares":213300}},"namedEntities":{"people":[{"name":"Sharon Klahre","role":"Syndax contact / investor relations"}],"products":["Revuforj (revumenib)","Niktimvo (axatilimab-csfr)"],"companies":[{"name":"Syndax Pharmaceuticals","ticker":"SNDX","relationship":"filer"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine NASDAQ Rule 5635(c)(4) inducement equity grants to nine new employees; boilerplate compensation disclosure with no financial or operational impact."},"tickerRelevance":{"others":[],"primary":"SNDX"},"globalImportance":5,"audienceRelevance":5,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap-biotech","eventGravity":"routine-inducement-grants","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Syndax Pharmaceuticals granted inducement stock options to purchase up to 213,300 shares to nine new employees on October 1, 2026, under its 2023 Inducement Plan.\n\nThe awards vest over four years with a standard one-year cliff at 25%, followed by monthly vesting over 36 months, subject to continued employment.\n\nThis is routine hiring-related equity disclosure under NASDAQ Listing Rule 5635(c)(4) with no bearing on strategy or financials.","key_figures":{"customDimensions":{"vesting":"4 years; 25% at one-year anniversary, then 1/48th monthly over 36 months","new_employees":9,"inducement_shares":213300}},"named_entities":{"people":[{"name":"Sharon Klahre","role":"Syndax contact / investor relations"}],"products":["Revuforj (revumenib)","Niktimvo (axatilimab-csfr)"],"companies":[{"name":"Syndax Pharmaceuticals","ticker":"SNDX","relationship":"filer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-02T20:01:04.447Z","global_importance":5,"audience_relevance":5,"importance_components":{"tickerTier":"mid-cap-biotech","eventGravity":"routine-inducement-grants","issuerAuthored":true}},"durationMs":3996,"modelName":"glm-5.3-flashx"}}